What are the causes of an increased international normalized ratio (INR) in patients taking Eliquis (apixaban)?

INR Does Not Reliably Measure Apixaban Activity and Should Not Be Used for Monitoring

An elevated INR in a patient taking Eliquis (apixaban) is typically a spurious laboratory finding caused by the drug's effect on the prothrombin time assay, not a true indicator of excessive anticoagulation or bleeding risk. The INR is designed to monitor warfarin therapy and is unreliable for assessing direct oral anticoagulants like apixaban 1.

Why INR Increases with Apixaban

Direct Drug Effect on Laboratory Testing

Apixaban, as a Factor Xa inhibitor, causes concentration-dependent prolongation of the prothrombin time (PT), which artificially elevates the INR 1. This is a pharmacodynamic artifact of the assay, not a reflection of true coagulation status:

• Expected INR elevation: Studies show 78-84% of patients on apixaban have INR values above the normal range (>1.1), with median values of 1.4-1.7 2, 3
• Dose-dependent effect: Higher apixaban concentrations produce greater INR elevations 4
• Reagent variability: The degree of INR prolongation varies significantly depending on which PT reagent the laboratory uses 1

Critically, the 2018 European Heart Rhythm Association guidelines explicitly state that "for apixaban, the PT cannot be used for assessing the anticoagulant effect" and that "the INR is unreliable for the evaluation of FXa inhibitory activity" 1.

When INR Elevation May Reflect True Coagulopathy

While apixaban itself causes INR elevation, you must distinguish this expected effect from genuine coagulopathy. Consider these alternative causes:

Hepatic dysfunction:

• Liver disease impairs synthesis of vitamin K-dependent clotting factors
• Check baseline liver function tests, bilirubin, and albumin 5
• If INR was normal before starting apixaban and liver function is stable, hepatic dysfunction is unlikely 6

Vitamin K deficiency:

• Malnutrition, prolonged antibiotic use (especially cefazolin), or malabsorption
• A case report documented INR >22.5 in a patient on apixaban receiving cefazolin with poor nutritional intake and COVID-19 7
• If vitamin K deficiency is present, INR should normalize with vitamin K administration 7

Drug interactions affecting coagulation:

• Warfarin co-administration or recent overlap during anticoagulant switching 1
• Antibiotics that deplete vitamin K (cephalosporins with N-methylthiotetrazole side chain) 7
• NSAIDs, antiplatelet agents, SSRIs/SNRIs that increase bleeding risk through separate mechanisms 8

Severe renal impairment:

• Apixaban undergoes 27% renal clearance 6
• In end-stage renal disease on hemodialysis, drug accumulation can occur
• One case report documented INR >27 in a dialysis patient on apixaban 2.5 mg twice daily 6
• However, even in this extreme case, the elevated INR was attributed to high apixaban concentration affecting the assay, not true coagulopathy 6

Clinical Approach to Elevated INR on Apixaban

Step 1: Assess for Active Bleeding

If bleeding is present:

• The INR value is irrelevant for management decisions
• Assess bleeding severity using clinical criteria (hemodynamic instability, hemoglobin drop ≥2 g/dL, transfusion requirement ≥2 units) 9
• For life-threatening bleeding, consider andexanet alfa for apixaban reversal 6
• Supportive care with transfusion as needed

If no bleeding:

• An elevated INR alone does not indicate need for reversal or dose adjustment 6
• The patient is likely not over-anticoagulated despite the elevated INR

Step 2: Determine if INR Elevation is Expected Drug Effect

Review timing:

• INR typically increases within 1 day of starting apixaban, with median values of 1.4 on day 1, rising to 1.5-1.7 by days 4-7 2
• Peak INR occurs 1.5-3.3 hours after dosing, corresponding to peak apixaban concentration 4

Check baseline INR:

• If INR was normal before starting apixaban, the elevation is likely drug-related 6
• If INR was already elevated, consider alternative causes

Verify apixaban dosing:

• Standard dose: 5 mg twice daily (or 10 mg twice daily for VTE treatment)
• Reduced dose: 2.5 mg twice daily (if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 10, 8
• Inappropriate standard dosing in patients requiring dose reduction can lead to higher drug concentrations and greater INR elevation 3

Step 3: Evaluate for Alternative Causes

Obtain:

• Liver function tests (AST, ALT, bilirubin, albumin, INR prior to apixaban if available)
• Renal function (creatinine clearance using Cockcroft-Gault equation)
• Medication review for recent antibiotic changes, warfarin overlap, or interacting drugs
• Nutritional assessment if malnutrition suspected

If vitamin K deficiency suspected:

• Administer vitamin K 5-10 mg IV 5, 7
• Recheck INR in 24-48 hours
• If INR normalizes, vitamin K deficiency was contributory
• If INR remains elevated but stable, apixaban effect is likely explanation

If hepatic dysfunction present:

• Apixaban is contraindicated in severe hepatic impairment 8
• Consider alternative anticoagulation strategy

If severe renal impairment (CrCl <15 mL/min or dialysis):

• Apixaban is not FDA-approved for this population 11, 10
• Consider measuring apixaban plasma concentration if available (therapeutic range 69-321 ng/mL at peak) 1
• Dose reduction or alternative anticoagulation may be needed

Step 4: Management Decision

Do NOT:

• Routinely hold or reduce apixaban dose based solely on elevated INR 1
• Administer vitamin K, fresh frozen plasma, or prothrombin complex concentrate unless true coagulopathy is confirmed 6
• Switch to warfarin based on INR concerns (warfarin requires INR monitoring; apixaban does not)

DO:

• Continue apixaban at appropriate dose if no bleeding and no alternative cause identified
• Document that INR elevation is expected with apixaban and does not require intervention
• Educate other providers that INR should not be checked routinely in patients on apixaban
• If apixaban concentration measurement is available and clinical concern exists, use chromogenic anti-Factor Xa assay calibrated for apixaban (not INR) 1, 9

Special Considerations

Perioperative management:

• INR cannot guide timing of procedures in apixaban patients 1
• Use time since last dose and renal function to estimate drug clearance
• Apixaban half-life is approximately 12 hours 4
• For high bleeding risk procedures, hold apixaban for 48 hours (4 half-lives) if CrCl >50 mL/min 9

Transitioning from apixaban to warfarin:

• Apixaban prolongs INR, making it difficult to determine when therapeutic warfarin effect is achieved 1
• Continue apixaban with warfarin for 2 days, then check INR 24 hours after stopping apixaban 8
• Do not rely on INR during overlap period

High-risk elderly patients:

• Therapeutic drug monitoring with apixaban plasma concentration (not INR) may be beneficial 12
• Target peak concentration 69-321 ng/mL 1
• Dose adjustment based on plasma concentration improved outcomes in one study 12

Common Pitfalls

1. Ordering INR routinely in apixaban patients: This generates unnecessary alarm and inappropriate interventions
2. Treating elevated INR as warfarin over-anticoagulation: Apixaban patients do not need vitamin K or reversal agents for elevated INR alone
3. Assuming bleeding risk correlates with INR: The INR does not predict bleeding risk in apixaban patients 1
4. Using point-of-care INR devices: These are even less reliable than laboratory INR for apixaban patients 1

1, 9, 8, 7, 6, 2, 3, 4